Amarin Announces Completion of Offering of American Depositary Shares
July 12, 2013 16:01 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, July 12, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin" or the "Company") today announced that it had completed its previously announced...
Amarin Announces Public Offering of American Depositary Shares
July 08, 2013 16:42 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, July 8, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) ("Amarin" or the "Company") today announced that it is offering to sell 21,700,000 American...
Amarin Announces Positive Results of Phase 1 Clinical Trial Measuring the Bioavailability of a Fixed-Dose Combination of Vascepa(R) and a Statin Compared to Concomitant Administration
June 21, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, June 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa(R) in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
June 19, 2013 07:59 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, June 19, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin to Present at the Jefferies 2013 Global Healthcare Conference
May 30, 2013 16:05 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Additional Effects of Vascepa(R) on Lipoprotein Particle Concentration From the ANCHOR Study Presented at the National Lipid Association 2013 Annual Scientific Sessions
May 30, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy
May 22, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, May 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations
May 09, 2013 16:05 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, May 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development...
Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013
May 03, 2013 16:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, May 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to...
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
April 30, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, April 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...